Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis

Lipids in Health and Disease

Li-Mei Fan²  Hui-Mei Yu⁴  He Zhu²  Chang-Jun Zheng²  Jia-Ling Zhang²  Wen-Chao Zhang³  Yi-Yang Li¹ 

[1] Department of Gynaecology, the First Hospital of Jilin University, Changchun 130041, China;Department of Gynaecology and Obstetrics, the Second Hospital of Jilin University, Ziqiang Street NO. 218, Nanguan District, Changchun 130041, People’s Republic of China;Center for Reproductive Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Deparment of Pathology and Pathophysiology, School of Basic Medical Sciences, Changchun 130021, China

关键词: Meta-analysis;    Bioactive phospholipid;    Ovarian cancer;    Lysophosphatidic acid;   

Others  :  1220955
DOI  :  10.1186/s12944-015-0071-9

 received in 2014-12-20, accepted in 2015-06-30,  发布年份 2015

【 摘 要 】

Background

In this study, using a meta-analysis approach, we examined the correlation between serum levels of lysophosphastidic acid (LPA) and ovarian cancer (OC).

Methods

Relevant published studies were identified from multiple scientific literature databases by using a pre-determined electronic and manual search strategy. The search results were screened through a multi-step process to select high-quality case–control studies suitable for the present meta-analysis. Mean values and standardized mean differences (SMD) were calculated for plasma LPA levels. Two investigators independently extracted the data from the studies and performed data analysis using STATA software version 12.0 (Stata Corp, College Station, TX, USA).

Results

Nineteen case–control studies met our selection criteria and contained a total of 980 OC patients, 872 benign controls and 668 healthy controls. Our meta-analysis results revealed that the plasma levels of LPA in OC patients were significantly higher than benign controls (SMD = 2.36, 95 % CI: 1.61–3.10, P <0.001) and healthy controls (SMD = 2.32, 95 % CI: 1.77–2.87, P <0.001). Subgroup analysis by ethnicity showed that the plasma LPA levels in OC patients were significantly higher than the benign controls only in Asian populations (SMD = 2.52, 95 % CI: 1.79–3.25, P <0.001). However, a comparison between healthy controls and OC patients revealed that, in both Asians and Caucasians, the OC patients displayed significantly higher plasma LPA levels compared to healthy controls (all P <0.05).

Conclusion

Our meta-analysis showed strong evidence that a significantly higher plasma LPA levels are present in OC patients, compared to benign controls and healthy controls, and plasma LPA levels may be used as a biomarker or target of OC.

【 授权许可】

   
2015 Li et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al.. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-86.
• [2]Kobayashi E, Ueda Y, Matsuzaki S, Yokoyama T, Kimura T, Yoshino K et al.. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21:1902-12.
• [3]Lowe KA, Chia VM, Taylor A, O’Malley C, Kelsh M, Mohamed M et al.. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013; 130:107-14.
• [4]Sedlakova I, Vavrova J, Tosner J, Hanousek L. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumour Biol. 2011; 32:311-6.
• [5]Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R et al.. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002; 1582:257-64.
• [6]Smicun Y, Reierstad S, Wang FQ, Lee C, Fishman DA. S1P regulation of ovarian carcinoma invasiveness. Gynecol Oncol. 2006; 103:952-9.
• [7]Wang FQ, Ariztia EV, Boyd LR, Horton FR, Smicun Y, Hetherington JA et al.. Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecol Oncol. 2010; 117:88-95.
• [8]Aoki J. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol. 2004; 15:477-89.
• [9]Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 1781; 2008:513-8.
• [10]Luquain C, Singh A, Wang L, Natarajan V, Morris AJ. Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells. J Lipid Res. 2003; 44:1963-75.
• [11]Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F et al.. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol. 2010; 21:248-54.
• [12]Wang DL, Chen LX, Liao XL, Liao XJ, Wu QH. The relationship of lysophosphatidic acid and MMP-2 in diagnosing epithelial ovarian carcinoma. Proc Clin Med. 2013; 22:403-5.
• [13]Ding F, Niu B. Clinical significance of detecting lysophosphatidic acid and vascular endothelial growth factor in patients with epithelial ovarian carcinoma. Practical J Med Pharmacy. 2013; 30:775-7.
• [14]Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R et al.. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007; 433:1-25.
• [15]Cao XY. The applicable value of combined detection of LPA, CA1 25 and AFP in the early diagnosis of ovarian cancer. Laboratory Med Clinic. 2008; 5:1430-1.
• [16]Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012; 31:3805-20.
• [17]Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006; 295:676-80.
• [18]Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005; 21:3672-3.
• [19]Pozlep B, Meleh M, Kobal B, Verdenik I, Osredkar J, Kralj LZ et al.. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors. Eur J Gynaecol Oncol. 2007; 28:394-9.
• [20]Zhang YM, Zhang XN. Expression of XIAP, Survivin, LPA and CA12 5 in human epithelial ovarian carcinoma. Journal of Shandong University (Health Science). 2007; 45:317-21.
• [21]Yan ZT, Huang N, Zhao ML, Pang AP. Clinical Values of serum CA125 and LPA determination in early diagnosis of ovarian cancer. Chinese Journal of Primary Medicine and Pharmacy. 2009; 16:1993-4.
• [22]Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P et al.. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998; 280:719-23.
• [23]Wang H, Chen DZ. Study on the diagnostic Value of Plasm a Lysopho sphatidic Acid (LPA) Level Determination in Patients with Ovarian Carcinoma. Journal of Radioimmunology. 2008; 21:355-7.
• [24]Liao JR, Zong JH, Lv YY. Detection of Plasma Iysophosphatidic Acid (LPA) in Epithelial Ovarian Tumor Patients. Inner Mongolia Medical Journal. 2010; 42:1295-6.
• [25]Liang HF, Zhang H, Ma XY. Comparative analysis of the value of lysophosphatidic acid and CA125 in the diagnosis of ovarian cancer. Clinical Medicine of China. 2011; 27:348-50.
• [26]Lian XF, Li XL, Zhan HL, Sun F. The diagnostic value when lysophospholipids acid, epididymis protein 4 used in early ovarian cancer’ s detection. International Medicine and Health Guidance News. 2010; 16:2778-81.
• [27]Li C, Fang SH, Chen W. The diagnostic value of sol uble P185 in ovarian cancer. Chinese Journal of Laboratory Diagnosis. 2007; 11:1238-9.
• [28]Lao M, Pan ZM, Huang WC, Huang LS, Zhu B, Zhao HL et al.. The value of plasma lysophosphatidic acid measurement in the diagnosis of gynecology tumor. The Practical Journal of Cancer. 2007; 22:347-9.
• [29]Guo HY, Han JS, Wu QZ, Yang CS. A study of diagnostic value of plasma lysophosphatidic acid for ovarian epithelial cancer. Chinese Journal of Clinical Obstetrics and Gynecology. 2002; 03:36-8.
• [30]Duan ML, Wu F. The diagnostic value of secretory phospholipase A2 and lysophosphatic acid for ovarian cancer. Chinese Journal of Laboratory Medicine. 2005; 28:622-4.
• [31]Du Y. Study on correlation between diagnosis of epithlial ovarian cancer and plasma lysophosphatidic acid. Zhejiang Medical Journal. 2005; 27:827-8.
• [32]Chen YN, Tao M, Tu FP, Zuo Y, Lu WD. LPA, IL-6 and IL-8 levels in the plasma of patients with epithelial ovarian carcinoma. The Practical Journal of Cancer. 2008; 23:580-2.
• [33]Hu YL, Albanese C, Pestell RG, Jaffe RB. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst. 2003; 95:733-40.
• [34]Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N et al.. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2001; 93:762-8.
• [35]Nakamura K, Igarashi K, Ohkawa R, Yokota H, Masuda A, Nakagawa S et al.. Serum autotaxin is not a useful biomarker for ovarian cancer. Lipids. 2012; 47:927-30.